Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution ...

Boston Scientific continues to deliver robust growth, but valuation limits upside despite strong execution and leading positions in key medical device markets. BSX's growth drivers—Farapulse (PFA), ...

In the latest close session, Boston Scientific (BSX) was down 1.02% at $91.75. The stock's change was less than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an upswing of 1.35%, while the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Boston Scientific has been ...

For me, buying a publicly traded stock is no different than buying an interest in a private business. In either case, I would only invest in a company that’s well-managed, with a valuable product line ...

Boston Scientific is one of those companies that most people never think about until they need it. Its products are not seen on drugstore shelves or marketed on television. Instead, they sit inside ...

We came across a bullish thesis on Boston Scientific Corporation on Value investing subreddit by Infinite_Spinach8839. In this article, we will summarize the bulls’ thesis on BSX. Boston Scientific ...

Boston Scientific bought its newly opened 400,000 sq. ft. Maple Grove facility from Ryan Cos. for $188.8 million. The office pricing sits at $472 per square foot, among the highest in years The site ...

Over the past several years, Boston Scientific BSX has pursued a series of acquisitions in support of its growth strategy, both strengthening its core businesses and expanding into high-growth ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...